Type 2 innate lymphoid cells participate in IL‑33‑stimulated Th2‑associated immune response in chronic obstructive pulmonary disease

Jiang,Min; Tao,Simin; Zhang,Shaohua; Wang,Jing; Zhang,Fengbo; Li,Fengsen; Ding,Jianbing

doi:10.3892/etm.2019.7924

Type 2 innate lymphoid cells participate in IL‑33‑stimulated Th2‑associated immune response in chronic obstructive pulmonary disease

Authors:
- Min Jiang
- Simin Tao
- Shaohua Zhang
- Jing Wang
- Fengbo Zhang
- Fengsen Li
- Jianbing Ding
View Affiliations

Affiliations: National Traditional Chinese Medicine Clinical Research Base, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Xinjiang Laboratory of Respiratory Disease Research, Urumqi, Xinjiang 830011, P.R. China, Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Department of Immunology, College of Basic Medicine, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China
Published online on: August 20, 2019 https://doi.org/10.3892/etm.2019.7924
Pages: 3109-3116

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the roles of type 2 innate lymphoid cells (ILC2s) and interleukin‑33 (IL‑33) in chronic obstructive pulmonary disease (COPD). Serum and peripheral blood mononuclear cells (PBMCs) were isolated from healthy controls and COPD patients. ILC2 cells from the peripheral blood of COPD patients were stimulated with IL‑33 or neutralizing ST2 antibody+IL‑33 in vitro. The cell viability was assessed using a Cell Counting Kit‑8 assay. ELISA was used to detect serum IL‑33 and the levels of IL‑4, IL‑5, IL‑6, IL‑13 and soluble ST2 (sST2) in the culture supernatant. The percentage of ILC2 cells was measured by flow cytometry. The mRNA expression levels of GATA binding protein 3 (GATA3), RAR‑related orphan receptor (ROR)α, ST2 and prostaglandin D2 receptor 2 (CRTH2) were detected by reverse transcription‑quantitative PCR. It was revealed that IL‑33, IL‑5, IL‑6 and IL‑13 were significantly elevated in peripheral blood of patients with COPD. The proportion of ILC2s in peripheral blood of COPD patients was significantly increased, and the expression of RORA and CRTH2 was increased. The proportion of ST2+ ILC2 cells was significantly increased. After 48 h of IL‑33 stimulation in vitro, the ratio of linage‑CD45+CD127+CRTH2+ cells reached a maximum. In addition, the viability of ILC2 cells, the expression levels of RORA, GATA3, ST2 and CRTH2 mRNA and the cytokines IL‑4, IL‑6, IL‑5, IL‑13 and sST2 were significantly increased. These effects were abrogated by treatment with anti‑ST2. In conclusion, IL‑33 is upregulated in the serum of patients with COPD and the proportion of ILC2s among the PBMCs is increased. IL‑33 may promote the proliferation of ILC2 cells and secrete type 2 T‑helper cell cytokines to participate in the immune response in COPD.

View Figures

View References

1	Blanchette CM, Gross NJ and Altman P: Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits. 7:98–106. 2014.PubMed/NCBI
2	Gupta D, Agarwal R, Aggarwal AN, Maturu VN, Dhooria S, Prasad KT, Sehgal IS, Yenge LB, Jindal A, Singh N, et al: Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India. 30:228–267. 2013. View Article : Google Scholar : PubMed/NCBI
3	Zhang Z, Cheng X, Yue L, Cui W, Zhou W, Gao J and Yao H: Molecular pathogenesis in chronic obstructive pulmonary disease and therapeutic potential by targeting AMP-activated protein kinase. J Cell Physiol. 233:1999–2006. 2018. View Article : Google Scholar : PubMed/NCBI
4	Kim SW, Rhee CK, Kim KU, Lee SH, Hwang HG, Kim YI, Kim DK, Lee SD, Oh YM and Yoon HK: Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 12:395–402. 2017. View Article : Google Scholar : PubMed/NCBI
5	Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO and Paré PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. New Engl J Med. 350:2645–2653. 2004. View Article : Google Scholar : PubMed/NCBI
6	Brusselle GG, Joos GF and Bracke KR: New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 378:1015–1026. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lee N, Shin MS and Kang I: T-cell biology in aging, with a focus on lung disease. J Gerontol A Biol Sci Med Sci. 67:254–263. 2012. View Article : Google Scholar : PubMed/NCBI
8	Molofsky AB, Savage AK and Locksley RM: Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity. 42:1005–1019. 2015. View Article : Google Scholar : PubMed/NCBI
9	Gordon ED, Simpson LJ, Rios CL, Ringel L, Lachowicz-Scroggins ME, Peters MC, Wesolowska-Andersen A, Gonzalez JR, MacLeod HJ, Christian LS, et al: Alternative splicing of interleukin-33 and type 2 inflammation in asthma. Proc Natl Acad Sci USA. 113:8765–8770. 2016. View Article : Google Scholar : PubMed/NCBI
10	Nasr WF, Sorour SS, El Bahrawy AT, Boghdadi GS and El Shahaway AA: The role of the level of interleukin-33 in the therapeutic outcomes of immunotherapy in patients with allergic rhinitis. Int Arch Otorhinolaryngol. 22:152–156. 2018. View Article : Google Scholar : PubMed/NCBI
11	Shan S, Li Y, Wang J, Lv Z, Yi D, Huang Q, Corrigan CJ, Wang W, Quangeng Z and Ying S: Nasal administration of interleukin-33 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma surrogate. Immunology. 148:83–91. 2016. View Article : Google Scholar : PubMed/NCBI
12	Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, Mori M, Pham TH, Ward CK, Criner GJ, et al: Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity. 42:566–579. 2015. View Article : Google Scholar : PubMed/NCBI
13	Xia J, Zhao J, Shang J, Li M, Zeng Z, Zhao J, Wang J, Xu Y and Xie J: Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 308:L619–L627. 2015. View Article : Google Scholar : PubMed/NCBI
14	Agapov E, Battaile JT, Tidwell R, Hachem R, Patterson GA, Pierce RA, Atkinson JJ and Holtzman MJ: Macrophage chitinase 1 stratifies chronic obstructive lung disease. Am J Respir Cell Mol Biol. 41:379–384. 2009. View Article : Google Scholar : PubMed/NCBI
15	Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH, Benoit LA, Byers DE, Alevy Y, Tucker J, et al: Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med. 14:633–640. 2008. View Article : Google Scholar : PubMed/NCBI
16	Shaykhiev R and Crystal RG: Innate immunity and chronic obstructive pulmonary disease: A mini-review. Gerontology. 59:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
17	Karta MR, Broide DH and Doherty TA: Insights into group 2 innate lymphoid cells in human airway disease. Curr Allergy Asthma Rep. 16:82016. View Article : Google Scholar : PubMed/NCBI
18	Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J, Ohtani M, Fujii H and Koyasu S: Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 463:540–544. 2010. View Article : Google Scholar : PubMed/NCBI
19	Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, et al: Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 464:1367–1370. 2010. View Article : Google Scholar : PubMed/NCBI
20	Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ and Locksley RM: Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA. 107:11489–11494. 2010. View Article : Google Scholar : PubMed/NCBI
21	Wong SH, Walker JA, Jolin HE, Drynan LF, Hams E, Camelo A, Barlow JL, Neill DR, Panova V, Koch U, et al: Transcription factor RORα is critical for nuocyte development. Nat Immunol. 13:229–236. 2012. View Article : Google Scholar : PubMed/NCBI
22	Doherty TA: At the bench: Understanding group 2 innate lymphoid cells in disease. J Leukoc Biol. 97:455–467. 2015. View Article : Google Scholar : PubMed/NCBI
23	Huang Y and Paul WE: Inflammatory group 2 innate lymphoid cells. Int Immunol. 28:23–28. 2016.PubMed/NCBI
24	Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, Huang LC, Johnson D, Scanlon ST, McKenzie AN, et al: A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 210:2939–2950. 2013. View Article : Google Scholar : PubMed/NCBI
25	De Grove KC, Provoost S, Verhamme FM, Bracke KR, Joos GF, Maes T and Brusselle GG: Characterization and quantification of innate lymphoid cell subsets in human lung. PLoS One. 11:e01459612016. View Article : Google Scholar : PubMed/NCBI
26	Oczypok EA, Milutinovic PS, Alcorn JF, Khare A, Crum LT, Manni ML, Epperly MW, Pawluk AM, Ray A and Oury TD: Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis through IL-33 and accumulation of group 2 innate lymphoid cells. J Allergy Clin Immunol. 136:747–756.e4. 2015. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Bhat TA, Panzica L, Kalathil SG and Thanavala Y: Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 12 (Suppl 2):S169–S175. 2015.PubMed/NCBI
29	Lefrançais E, Duval A, Mirey E, Roga S, Espinosa E, Cayrol C and Girard JP: Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci USA. 111:15502–15507. 2014. View Article : Google Scholar : PubMed/NCBI
30	Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DM and Artis D: IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA. 112:10762–10767. 2015. View Article : Google Scholar : PubMed/NCBI
31	Mizutani N, Nabe T and Yoshino S: Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice. Immunology. 139:205–218. 2013. View Article : Google Scholar : PubMed/NCBI
32	Smith D, Helgason H, Sulem P, Bjornsdottir US, Lim AC, Sveinbjornsson G, Hasegawa H, Brown M, Ketchem RR, Gavala M, et al: A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genet. 13:e10066592017. View Article : Google Scholar : PubMed/NCBI
33	Xu H, Turnquist HR, Hoffman R and Billiar TR: Role of the IL-33-ST2 axis in sepsis. Mil Med Res. 4:32017. View Article : Google Scholar : PubMed/NCBI
34	McKenzie AN: Type-2 innate lymphoid cells in asthma and allergy. Ann Am Thorac Soc. 11 (Suppl 5):S263–S270. 2014. View Article : Google Scholar : PubMed/NCBI
35	Mortaz E, Folkerts G and Redegeld F: Mast cells and COPD. Pulm Pharmacol Ther. 24:367–372. 2011. View Article : Google Scholar : PubMed/NCBI
36	Mohapatra A, Van Dyken SJ, Schneider C, Nussbaum JC, Liang HE and Locksley RM: Group 2 innate lymphoid cells utilize the IRF4-IL-9 module to coordinate epithelial cell maintenance of lung homeostasis. Mucosal Immunol. 9:275–286. 2016. View Article : Google Scholar : PubMed/NCBI
37	Silver JS, Kearley J, Copenhaver AM, Sanden C, Mori M, Yu L, Pritchard GH, Berlin AA, Hunter CA, Bowler R, et al: Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat Immunol. 17:626–635. 2016. View Article : Google Scholar : PubMed/NCBI
38	Mjösberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, Fokkens WJ, Cupedo T and Spits H: Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 12:1055–1062. 2011. View Article : Google Scholar : PubMed/NCBI
39	Stier MT, Zhang J, Goleniewska K, Cephus JY, Rusznak M, Wu L, Van Kaer L, Zhou B, Newcomb DC and Peebles RS Jr: IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow. J Exp Med. 215:263–281. 2018. View Article : Google Scholar : PubMed/NCBI
40	Doherty TA, Khorram N, Chang JE, Kim HK, Rosenthal P, Croft M and Broide DH: STAT6 regulates natural helper cell proliferation during lung inflammation initiated by Alternaria. Am J Physiol Lung Cell Mol Physiol. 303:L577–L588. 2012. View Article : Google Scholar : PubMed/NCBI
41	Riedel JH, Becker M, Kopp K, Düster M, Brix SR, Meyer-Schwesinger C, Kluth LA, Gnirck AC, Attar M, Krohn S, et al: IL-33-mediated expansion of type 2 innate lymphoid cells protects from progressive glomerulosclerosis. J Am Soc Nephrol. 28:2068–2080. 2017. View Article : Google Scholar : PubMed/NCBI
42	Furusawa J, Moro K, Motomura Y, Okamoto K, Zhu J, Takayanagi H, Kubo M and Koyasu S: Critical role of p38 and GATA3 in natural helper cell function. J Immunol. 191:1818–1826. 2013. View Article : Google Scholar : PubMed/NCBI
43	Chang J, Xia YF, Zhang MZ and Zhang LM: IL-33 signaling in lung injury. Transl Perioper Pain Med. 1:24–32. 2016.PubMed/NCBI
44	Hayakawa H, Hayakawa M and Tominaga SI: Soluble ST2 suppresses the effect of interleukin-33 on lung type 2 innate lymphoid cells. Biochem Biophys Rep. 5:401–407. 2016.PubMed/NCBI